Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial

Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Jordy P. W., van Lochem, Ellen G., Roovers, Elisabeth A., Drenth, Joost P. H., Wahab, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/
https://www.ncbi.nlm.nih.gov/pubmed/35565738
http://dx.doi.org/10.3390/nu14091771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/
https://www.ncbi.nlm.nih.gov/pubmed/35565738
http://dx.doi.org/10.3390/nu14091771

Ejemplares similares